Q3 Earnings Forecast for Soligenix Issued By Zacks Research

Soligenix Inc. (NASDAQ:SNGX) – Analysts at Zacks Research boosted their Q3 2026 earnings estimates for shares of Soligenix in a research report issued on Wednesday, August 12th. Zacks Research analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.21). The consensus estimate for Soligenix’s current full-year earnings is ($0.55) per share. Zacks Research also issued estimates for Soligenix’s Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.40) EPS and FY2028 earnings at ($0.38) EPS.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.04.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Soligenix has an average rating of “Sell”.

Soligenix Stock Up 3.9%

SNGX opened at $0.40 on Monday. The company has a market cap of $5.87 million, a price-to-earnings ratio of -0.40 and a beta of 1.93. Soligenix has a 52-week low of $0.28 and a 52-week high of $4.30. The firm’s fifty day simple moving average is $0.39 and its two-hundred day simple moving average is $0.76.

Institutional Trading of Soligenix

Institutional investors have recently made changes to their positions in the company. Armistice Capital LLC acquired a new position in Soligenix in the 3rd quarter valued at $821,000. Two Sigma Investments LP acquired a new stake in Soligenix during the 3rd quarter worth $102,000. Geode Capital Management LLC boosted its stake in Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 37,811 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Soligenix during the third quarter worth $59,000. Finally, Banco BTG Pactual S.A. purchased a new stake in shares of Soligenix during the third quarter worth $54,000. 3.60% of the stock is owned by institutional investors and hedge funds.

Soligenix Company Profile

Soligenix, Inc is a clinical?stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small?molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.